{
  "meta": {
    "title": "Introduction_To_Endocrinology_Pituitary_Disorders",
    "url": "https://brainandscalpel.vercel.app/introduction-to-endocrinology-pituitary-disorders-2a55adf0.html",
    "scrapedAt": "2025-11-29T18:24:43.497Z"
  },
  "questions": [
    {
      "id": 53809,
      "choices": [
        {
          "id": 214709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Activates a GPCR increasing cAMP. </span></span></span></p>"
        },
        {
          "id": 214710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Directly activates PKC. </span></span></span></p>"
        },
        {
          "id": 214711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Binds nuclear receptor. </span></span></span></p>"
        },
        {
          "id": 214712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Interacts with tyrosine kinase receptor.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old woman presents with complaints of polyuria (excessive urination), polydipsia (excessive thirst), and fatigue. Laboratory results reveal hyperglycemia and glucosuria. Which of the following best describes the mechanism of action of the hormone likely deficient in this patient?</span></span></span></p>",
      "unique_key": "Q5509148",
      "question_audio": null,
      "question_video": null,
      "map_id": 25404,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Interacts with tyrosine kinase receptor.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms are classic for diabetes mellitus, a condition characterized by insulin deficiency or resistance. Insulin is a peptide hormone (Group II) that binds to tyrosine kinase receptors on target cells. This binding triggers autophosphorylation of the receptor and subsequent activation of intracellular signaling cascades, leading to increased glucose uptake and utilization.<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Activates a GPCR increasing cAMP:</span></strong><span style=\"font-size:12.0pt\"> This mechanism is characteristic of some Group II hormones (e.g., glucagon), but not insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Directly activates PKC:</span></strong><span style=\"font-size:12.0pt\"> While PKC activation can occur downstream of insulin signaling, it is not the primary mechanism of action.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Binds nuclear receptor:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This mechanism is characteristic of Group I hormones (e.g., steroid hormones, thyroid hormones)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin interacts with tyrosine kinase receptors on target cells to mediate its effects.</span></span></span></p>",
      "correct_choice_id": 214712,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53849,
      "choices": [
        {
          "id": 214869,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Falsely low PRL levels can be due to macroprolactinemia.</span></span></span></p>"
        },
        {
          "id": 214870,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hook effect causes falsely elevated values of prolactin.</span></span></span></p>"
        },
        {
          "id": 214871,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common symptom in women is galactorrhea.</span></span></span></p>"
        },
        {
          "id": 214872,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can be associated with reduced Bone Mineral Density.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is true regarding hyperprolactinemia?</span></span></p>",
      "unique_key": "Q9161599",
      "question_audio": null,
      "question_video": null,
      "map_id": 25435,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Can be associated with reduced Bone Mineral Density</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism (since PRL suppresses GnRH release </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> it results in low FSH/LH and subsequent hypoestrogenism). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Falsely low PRL levels can be due to</span></strong><span style=\"font-size:12.0pt\"> <strong>macroprolactinemia</strong>: Macroprolactinemia is caused by aggregated forms of circulating PRL, which are usually biologically inactive. This can result in falsely increased PRL values.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hook effect causes falsely elevated values of prolactin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Markedly elevated PRL levels (&gt;1000 &mu;g/L), can result in falsely low PRL values because of assay artifacts (the hook effect). Sample dilution is required to measure these high values accurately<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Most common symptom in women is galactorrhea:</span></strong><span style=\"font-size:12.0pt\"> Most common symptom in women is gonadal dysfunction (galctorrhea occurs in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 80% women)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hyperprolactinemia can reduce vertebral bone mineral density due to hypogonadism caused by prolactin suppressing GnRH release, resulting in low FSH/LH and subsequent hypoestrogenism.</span></span></span></p>",
      "correct_choice_id": 214872,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53813,
      "choices": [
        {
          "id": 214725,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptor (GR) </span></span></span></p>"
        },
        {
          "id": 214726,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone receptor (TR) </span></span></span></p>"
        },
        {
          "id": 214727,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin D receptor (VDR) </span></span></span></p>"
        },
        {
          "id": 214728,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Retinoic acid receptor (RAR)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following steroid receptors primarily functions as a homodimer upon ligand binding?</span></span></p>",
      "unique_key": "Q3343886",
      "question_audio": null,
      "question_video": null,
      "map_id": 25408,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. A) Glucocorticoid receptor (GR)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoid receptors (GRs) typically form homodimers upon binding to their ligand (cortisol). This homodimer then translocates to the nucleus, where it binds to specific DNA sequences called glucocorticoid response elements (GREs) to regulate gene expression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Thyroid hormone receptor (TR):</span></strong><span style=\"font-size:12.0pt\"> TRs typically form heterodimers with retinoid X receptors (RXRs).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Vitamin D receptor (VDR):</span></strong><span style=\"font-size:12.0pt\"> VDRs also primarily form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Retinoic acid receptor (RAR):</span></strong><span style=\"font-size:12.0pt\"> RARs predominantly form heterodimers with RXRs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Homodimer (Steroid) Receptors - ER, AR, PR, GR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytoplasmic in location. Translocates to nucleus after binding to a ligand (also called as type 1 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligands usually induce coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Heterodimer Receptors - TR, VDR, RAR, PPAR</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location (also called as type 2 nuclear receptors)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ligand dissociates corepressors and induces coactivator binding</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Orphan Receptors - SF-1, DAX-1, HNF4&alpha;</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nuclear in location and they do not have known agonists (bind to nuclear intermediates)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Action may be ligand independent &amp; can be homo-dimeric or hetero-dimeric</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-152909.png\" style=\"height:339px; width:500px\" /></span></span></span></p>",
      "correct_choice_id": 214725,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53853,
      "choices": [
        {
          "id": 214885,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Octreotide </span></span></span></p>"
        },
        {
          "id": 214886,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Lanreotide </span></span></span></p>"
        },
        {
          "id": 214887,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pegvisomant </span></span></span></p>"
        },
        {
          "id": 214888,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pasireotide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 48-year-old woman with acromegaly is currently being treated with a drug but her growth hormone (GH) levels remain paradoxically elevated. Which of the following medications is she most likely taking?</span></span></p>",
      "unique_key": "Q4047374",
      "question_audio": null,
      "question_video": null,
      "map_id": 25439,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Pegvisomant</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant is a GH receptor antagonist. It works by blocking the action of GH at its receptor, thereby reducing IGF-1 production and effectively treating the symptoms of acromegaly. However, it increases GH resistance and hence, GH levels may remain elevated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Octreotide and Option B. Lanreotide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">SRLs (somatostatin receptor ligand)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduces GH and IGF-1 levels and reduces pituitary tumor size in ~50% of patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All SRLs can cause GI side effects, glucose intolerance (or diabetes), cholesterol gall stones, asymptomatic bradycardia and hypothyroxinemia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Octreotide is available as LAR and oral forms. Lanreotide is available as slow release depot formulation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pasireotide:</span></strong><span style=\"font-size:12.0pt\"> SRL specific for SST5 &ndash; can be used if resistant to octreotide or lanreotide. Higher prevalence of glucose intolerance and diabetes. Available as LAR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pegvisomant, a GH receptor antagonist, can cause paradoxically elevated GH levels despite reducing IGF-1 production and treating symptoms of acromegaly.</span></span></span></p>",
      "correct_choice_id": 214887,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53846,
      "choices": [
        {
          "id": 214857,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Surgical resection</span></span></span></p>"
        },
        {
          "id": 214858,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Radiotherapy </span></span></span></p>"
        },
        {
          "id": 214859,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs </span></span></span></p>"
        },
        {
          "id": 214860,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old child presents with precocious puberty, psychomotor delay, and laughing seizures. What is the first-line treatment?</span></span></p>",
      "unique_key": "Q1672044",
      "question_audio": null,
      "question_video": null,
      "map_id": 25432,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GnRH analogs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms suggest hypothalamic hamartoma, a benign tumor associated with a typical triad of&nbsp; precocious puberty, psychomotor delay, and gelastic (laughing) seizures. GnRH analogs suppress the HPG axis, halting precocious puberty.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Surgical resection:</span></strong><span style=\"font-size:12.0pt\"> Reserved for severe or refractory cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Radiotherapy:</span></strong><span style=\"font-size:12.0pt\"> Not preferred in children due to long-term side effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH:</span></strong><span style=\"font-size:12.0pt\"> Not relevant to precocious puberty treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GnRH analogs are the first-line treatment for precocious puberty associated with hypothalamic hamartoma.</span></span></span></p>",
      "correct_choice_id": 214859,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53818,
      "choices": [
        {
          "id": 214745,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal adult serum PRL levels are about 10&ndash;25 &micro;g/mL in women </span></span></span></p>"
        },
        {
          "id": 214746,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 a.m </span></span></span></p>"
        },
        {
          "id": 214747,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks occurring during rapid eye movement (REM) sleep </span></span></span></p>"
        },
        {
          "id": 214748,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Circulating half-life of PRL is ~50 min</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are true about Prolactin except:</span></span></p>",
      "unique_key": "Q2966081",
      "question_audio": null,
      "question_video": null,
      "map_id": 25413,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans. C)</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Highest secretory peaks occurring during rapid eye movement (REM) sleep</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While prolactin levels do increase during sleep, the highest secretory peaks actually occur during the non-REM (NREM) stages, particularly slow-wave sleep. REM sleep is associated with a relative decrease in prolactin secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Normal adult serum PRL levels are about 10-25 ng/mL in women:</span></strong><span style=\"font-size:12.0pt\"> This is the typical range for non-pregnant women. Normal serum PRL levels in men are about 10-25 ng/mL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Peak serum PRL levels (up to 30 &micro;g /mL) occur between 4:00 and 6:00 AM:</span></strong><span style=\"font-size:12.0pt\"> Prolactin levels follow a circadian rhythm, with the highest levels occurring during the early morning hours.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Circulating half-life of PRL is ~50 min:</span></strong><span style=\"font-size:12.0pt\"> Prolactin is relatively quickly cleared from the bloodstream, since it is a polypeptide.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Highest secretory peaks of prolactin occur during non-REM (NREM) sleep, not REM sleep.</span></span></span></p>",
      "correct_choice_id": 214747,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53844,
      "choices": [
        {
          "id": 214849,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Anterior </span></span></span></p>"
        },
        {
          "id": 214850,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central </span></span></span></p>"
        },
        {
          "id": 214851,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ventromedial </span></span></span></p>"
        },
        {
          "id": 214852,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Posterior</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old boy has been diagnosed with craniopharyngioma. He also has hyperphagia and obesity. This is seen in damage to which of the hypothalamic nuclei? </span></span></p>",
      "unique_key": "Q5363827",
      "question_audio": null,
      "question_video": null,
      "map_id": 25430,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Ventromedial</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperphagia (excessive eating) and obesity are characteristic symptoms of damage to the <strong>ventromedial nucleus (VMN)</strong> of the hypothalamus. The VMN is a key satiety center containing melanocortin receptors and regulated by leptin, insulin and POMC. Damage to this area can lead to a loss of satiety signals, resulting in overeating and obesity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Paradoxical vasoconstriction, tachycardia, and hyperthermia</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Central:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Excess sympathetic activity </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Posterior:</span></strong><span style=\"font-size:12.0pt\"> Lesions result in Periodic Hypothermia syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Damage to the ventromedial nucleus of the hypothalamus leads to hyperphagia and obesity due to loss of satiety signals.</span></span></span></p>",
      "correct_choice_id": 214851,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53858,
      "choices": [
        {
          "id": 214905,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intravenous hypertonic saline (3%) </span></span></span></p>"
        },
        {
          "id": 214906,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
        },
        {
          "id": 214907,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Demeclocycline </span></span></span></p>"
        },
        {
          "id": 214908,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tolvaptan</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old male smoker presents with mild confusion and nausea. He has a serum sodium of 125 mEq/L and a urine osmolality of 450 mOsm/kg. His BP and JVP are normal. Which of the following is the most appropriate initial treatment for him?</span></span></p>",
      "unique_key": "Q4193613",
      "question_audio": null,
      "question_video": null,
      "map_id": 25444,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Fluid restriction</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is SIADH (history of smoking may suggest a possible small cell lung cancer). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For hyponatremia due to SIADH (without severe symptoms), the initial treatment of choice is fluid restriction. This helps correct hyponatremia by limiting water intake and allowing the body to naturally excrete excess water.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Intravenous hypertonic saline (3%):</span></strong><span style=\"font-size:12.0pt\"> This is reserved for severe hyponatremia (&lt;120 mEq/L) with significant neurological symptoms (coma, seizures)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Demeclocycline:</span></strong><span style=\"font-size:12.0pt\"> This is a tetracycline antibiotic that can be used for chronic SIADH but is not the initial treatment for mild cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tolvaptan:</span></strong><span style=\"font-size:12.0pt\"> This is a vasopressin receptor antagonist used for SIADH, but it is not the first-line treatment for mild cases due to its potential side effects and cost.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction is the initial treatment of choice for hyponatremia due to SIADH without severe symptoms.</span></span></span></p>",
      "correct_choice_id": 214906,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53842,
      "choices": [
        {
          "id": 214841,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary adenomas frequently extend in a suprasellar direction. </span></span></span></p>"
        },
        {
          "id": 214842,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache is a common feature.</span></span></span></p>"
        },
        {
          "id": 214843,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity correlates with adenoma size or extension. </span></span></span></p>"
        },
        {
          "id": 214844,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Suprasellar extension can lead to visual loss.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old lady presented with headache. MRI revealed a pituitary tumor. All of the following are true except?</span></span></p>",
      "unique_key": "Q6721071",
      "question_audio": null,
      "question_video": null,
      "map_id": 25428,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Headache severity correlates with adenoma size or extension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headaches are common features of small intrasellar tumors, even without suprasellar extension. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Because of the confined nature of the pituitary, small changes in intrasellar pressure stretch the dural plate; however, headache severity correlates poorly with adenoma size or extension.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenomas frequently extend in a suprasellar direction:</span></strong><span style=\"font-size:12.0pt\"> Pituitary tumors often grow upwards towards the optic chiasm.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Headache is a common feature:</span></strong><span style=\"font-size:12.0pt\"> Headaches are a frequent symptom of pituitary tumors, often due to pressure effects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Suprasellar extension can lead to visual loss:</span></strong><span style=\"font-size:12.0pt\"> Upward growth of a pituitary tumor can compress the optic chiasm, leading to visual field defects or loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Headache severity in pituitary adenomas does not correlate well with tumor size or extension.</span></span></span></p>",
      "correct_choice_id": 214843,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53820,
      "choices": [
        {
          "id": 214753,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic glucocorticoid excess decreases GH release. </span></span></span></p>"
        },
        {
          "id": 214754,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 inhibits GH. </span></span></span></p>"
        },
        {
          "id": 214755,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to reduced lean body mass. </span></span></span></p>"
        },
        {
          "id": 214756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGFBP3 is the major carrier protein for IGF-1.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false regarding GH and IGF-1?</span></span></p>",
      "unique_key": "Q4099554",
      "question_audio": null,
      "question_video": null,
      "map_id": 25415,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) GH stimulates lipolysis, leading to reduced lean body mass.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis (breakdown of fats), but this process actually leads to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic glucocorticoid excess decreases GH release:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids can suppress GH secretion and can result in growth failure in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IGF-1 inhibits GH:</span></strong><span style=\"font-size:12.0pt\"> IGF-1, which is produced in response to GH, acts as a negative feedback signal to inhibit further GH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGFBP3 is the major carrier protein for IGF-1:</span></strong><span style=\"font-size:12.0pt\"> IGFBP3 is the most abundant IGF-binding protein in circulation and plays a crucial role in regulating IGF-1 bioavailability and activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary of GH and IGF-1:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">50% of anterior pituitary cell population is somatotrophs (that secrete GH)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is pulsatile and highest at night.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion is increased by GHRH, ghrelin and decreased by somatostatin &amp; IGF-1. Chronic glucocorticoid use can suppress GH secretion and can result in growth failure in children. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH secretion declines with age&nbsp; (correlates with age related sarcopenia) and obesity (IGF-1 levels in obesity may be normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH induces insulin resistance, protein synthesis, nitrogen retention, lipolysis, and sodium and water retention. GH also promotes linear bone growth.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most GH effects are mediated indirectly through somatomedins (IGF-1 is the most important somoatomedin).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 is the major somatomedin and primarily produced in the liver in response to GH. IGF-1 is bound to IGFBPs in circulation (most important is IGFBP3).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 side effects include hypoglycemia, hypotension, fluid retention, TMJ pain, and increased intracranial pressure and possibly can cause retinal damage and avascular femoral head necrosis. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH stimulates lipolysis, leading to an increase in lean body mass and a decrease in fat mass.</span></span></span></p>",
      "correct_choice_id": 214755,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53841,
      "choices": [
        {
          "id": 214837,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Active neoplasm </span></span></span></p>"
        },
        {
          "id": 214838,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intracranial hypertension </span></span></span></p>"
        },
        {
          "id": 214839,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Uncontrolled diabetes</span></span></span></p>"
        },
        {
          "id": 214840,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 41-year-old man with a history of cranial radiation is considered for GH therapy. Which of the following is NOT a contraindication? </span></span></p>",
      "unique_key": "Q2843550",
      "question_audio": null,
      "question_video": null,
      "map_id": 25427,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypertension.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypertension can be a consideration and requires monitoring during GH therapy, it is not an absolute contraindication. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Contraindications to GH therapy in adults are: active neoplasm, intracranial hypertension, uncontrolled diabetes, retinopathy</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Active neoplasm:</span></strong><span style=\"font-size:12.0pt\"> GH can potentially stimulate the growth of existing tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intracranial hypertension:</span></strong><span style=\"font-size:12.0pt\"> GH can worsen intracranial pressure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Uncontrolled diabetes:</span></strong><span style=\"font-size:12.0pt\"> GH can impair glucose tolerance and worsen glycemic control.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an absolute contraindication for GH therapy.</span></span></span></p>",
      "correct_choice_id": 214840,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53835,
      "choices": [
        {
          "id": 214813,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pituitary apoplexy </span></span></span></p>"
        },
        {
          "id": 214814,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sheehan syndrome </span></span></span></p>"
        },
        {
          "id": 214815,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis </span></span></span></p>"
        },
        {
          "id": 214816,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolactinoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32-year-old woman presents six weeks postpartum with headaches and visual disturbances. Her ESR is elevated, Prolactin levels are mildly increased, and MRI reveals a pituitary mass. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7004971",
      "question_audio": null,
      "question_video": null,
      "map_id": 25421,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Lymphocytic hypophysitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The likely diagnosis is lymphocytic hypophysitis, which commonly occurs in postpartum women. Most patients have elevated ESR, mildly elevated Prolactin levels and MRI findings usually resemble an adenoma. Usually has a good prognosis if treated early with glucocorticoids.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary apoplexy:</span></strong><span style=\"font-size:12.0pt\"> It is an acute hemorrhagic or ischemic event in the pituitary and presents with sudden onset of severe headache, visual loss, and ophthalmoplegia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Sheehan syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is postpartum hypopituitarism caused by ischemic necrosis of the pituitary gland, usually presenting with lactational failure. Prolactin levels would be low and high ESR in this case cannot be explained by Sheehan&rsquo;s syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Prolactinoma:</span></strong><span style=\"font-size:12.0pt\"> Close differential but high ESR points towards and inflammatory process than a prolactinoma. To differentiate &ndash; can consider a trial of glucocorticoids</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lymphocytic hypophysitis is a postpartum condition characterized by headaches, visual disturbances, elevated ESR, mildly increased prolactin levels, and MRI findings resembling a pituitary adenoma.</span></span></span></p>",
      "correct_choice_id": 214815,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53845,
      "choices": [
        {
          "id": 214853,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pituitary adenoma </span></span></span></p>"
        },
        {
          "id": 214854,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Craniopharyngioma </span></span></span></p>"
        },
        {
          "id": 214855,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Germinoma </span></span></span></p>"
        },
        {
          "id": 214856,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pinealoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old boy presents with headaches, visual field deficits, and growth retardation. CT scan of the head is shown. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164409.png\" style=\"height:364px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q1423220",
      "question_audio": null,
      "question_video": null,
      "map_id": 25431,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Craniopharyngioma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of symptoms: headaches, visual field deficits, and growth retardation (due to pituitary hormone deficiencies) with imaging typically showing suprasellar mass with calcifications suggests a diagnosis of craniopharyngioma. Craniopharyngiomas are benign tumors that arise from Rathke&#39;s pouch remnants.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Pituitary adenoma:</span></strong><span style=\"font-size:12.0pt\"> While pituitary adenomas can cause similar symptoms, they are less likely to present with calcifications and typically arise within the pituitary gland itself, not in the suprasellar region.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Germinoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors are more common in the pineal gland and usually present with Parinaud syndrome (upward gaze palsy, pupillary abnormalities) and obstructive hydrocephalus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pinealoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors arise from the pineal gland and can also present with Parinaud syndrome and obstructive hydrocephalus. They are less likely to have a cystic appearance with calcifications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Important DD for sellar/suprasellar masses:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Craniopharyngioma: </span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benign, suprasellar cystic masses derived from Rathke&#39;s pouch.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents with a triad of headaches, visual field deficits, and hypopituitarism.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presents usually &lt; 20 years if age and the most common type is adamantinomatous (large, cystic, lobulated, locally invasive, and partially calcified, usually has CTNNB1 (&beta;-catenin gene mutations)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypopituitarism is seen in ~90% and diabetes insipidus in ~10%. So, most patients require lifelong pituitary hormone replacement.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Treatment: Surgical resection followed by radiation of residual tumor (Surgery alone is curative in only &lt;50% cases due to recurrences. Radiotherapy improves 10-year survival to 70-90% but slightly increases the risk of secondary malignancies).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BRAF inhibitors may be effective in some cases with BRAF V600E mutations (especially in the adult papillary types). </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Rathke&#39;s Cysts:</span></strong></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Occues due to failure of Rathke&#39;s pouch obliteration.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mostly asymptomatic. ~33% present in adulthood with compressive symptoms, diabetes insipidus, and hyperprolactinemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pathognomonic large dot sign in MRI</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-164911.png\" style=\"height:610px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Craniopharyngiomas commonly present with headaches, visual field deficits, and growth retardation, and are characterized by suprasellar masses with calcifications on imaging.</span></span></span></p>",
      "correct_choice_id": 214854,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53811,
      "choices": [
        {
          "id": 214717,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
        },
        {
          "id": 214718,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
        },
        {
          "id": 214719,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
        },
        {
          "id": 214720,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">cAMP/PKA pathway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old patient presents with large hands, coarse face and headache. MRI shows a pituitary tumor. Which of the following signaling pathways is most likely activated by the hormone involved in the pathology?</span></span></p>",
      "unique_key": "Q6516191",
      "question_audio": null,
      "question_video": null,
      "map_id": 25406,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) JAK-STAT pathway</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is suffering from acromegaly and it is due to Growth hormone (GH) excess. Growth hormone receptors belong to the class of cytokine receptors that primarily signal through the JAK-STAT pathway. This pathway leads to the activation of transcription factors involved in growth and metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> While GH can activate MAPK pathways, it&#39;s not the primary signaling mechanism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> GH also activates the PI3K/Akt pathway, but it&#39;s not the primary pathway.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. cAMP/PKA pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily activated by G-protein coupled receptors, not GH receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth hormone (GH) primarily signals through the JAK-STAT pathway.</span></span></span></p>",
      "correct_choice_id": 214717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53837,
      "choices": [
        {
          "id": 214821,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">III cranial nerve (CN) palsy </span></span></span></p>"
        },
        {
          "id": 214822,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension </span></span></span></p>"
        },
        {
          "id": 214823,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoglycaemia </span></span></span></p>"
        },
        {
          "id": 214824,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Visual field defects</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman with a known pituitary adenoma presents to the emergency department with sudden onset of severe headache, visual disturbances, and vomiting. Which of the following is NOT an expected complication?</span></span></p>",
      "unique_key": "Q8957283",
      "question_audio": null,
      "question_video": null,
      "map_id": 25423,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypertension</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This is a case of pituitary apoplexy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Causes:</span></strong><span style=\"font-size:12.0pt\"> Hemorrhage into a pre-existing adenoma (most common), Sheehan&#39;s syndrome</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Risk Factors:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary adenoma, Diabetes, Hypertension, Sickle cell disease, PPH/shock</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Symptoms &amp; Complications:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Severe headache with meningeal irritation , visual field defects, Ophthalmoplegia (Most commonly III &gt; VI CN palsy</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Can cause Cardiovascular collapse and/or Loss of consciousness (in severe cases).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Severe hypoglycemia, Hypotension and shock, Death</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Diagnosis:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary CT or MRI (usually shows sellar mass with hemorrhage)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Management:</span></strong><span style=\"font-size:12.0pt\"> High dose glucocorticoids. Urgent surgery if LOC/ophthalmoplegia</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. III CN palsy:</span></strong><span style=\"font-size:12.0pt\"> Most common cranial nerve injured in apoplexy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypoglycemia:</span></strong><span style=\"font-size:12.0pt\"> Hypopituitarism can result in secondary adrenal insufficiency, leading to low cortisol levels and hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Visual field defects:</span></strong><span style=\"font-size:12.0pt\"> Compression of the optic chiasm by the pituitary mass can cause bitemporal hemianopsia or other visual field defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension is not an expected complication of pituitary apoplexy.</span></span></span></p>",
      "correct_choice_id": 214822,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53810,
      "choices": [
        {
          "id": 214713,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">JAK-STAT pathway </span></span></span></p>"
        },
        {
          "id": 214714,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAPK pathway </span></span></span></p>"
        },
        {
          "id": 214715,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PI3K/Akt pathway </span></span></span></p>"
        },
        {
          "id": 214716,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smad pathway</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with progressive muscle weakness and a distinctive heliotrope rash around her eyes. A muscle biopsy reveals endomysial inflammation and fibrosis. Which of the following signaling pathways is most likely implicated in the pathogenesis of her condition? </span></span></p>",
      "unique_key": "Q9363324",
      "question_audio": null,
      "question_video": null,
      "map_id": 25405,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Smad pathway </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with dermatomyositis, an autoimmune inflammatory myopathy. Transforming growth factor beta (TGF-&beta;) plays a crucial role in the pathogenesis of dermatomyositis, and its signaling occurs through the Smad pathway, leading to fibrosis and muscle damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. JAK-STAT pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is primarily involved in cytokine signaling and immune responses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. MAPK pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in various cellular processes, including proliferation and differentiation, but is not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PI3K/Akt pathway:</span></strong><span style=\"font-size:12.0pt\"> This pathway is involved in cell survival and growth, but not the primary pathway implicated in dermatomyositis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Receptor Tyrosine Kinase -&nbsp; Insulin, IGF-I EGF, NGF</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cytokine Receptor Linked Kinase - GH, PRL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serine Kinase - Activin, TGF-&beta;, MIS</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-150602.png\" style=\"height:342px; width:500px\" /></span></span></span></p>",
      "correct_choice_id": 214716,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53855,
      "choices": [
        {
          "id": 214893,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Central diabetes insipidus (DI) </span></span></span></p>"
        },
        {
          "id": 214894,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nephrogenic DI </span></span></span></p>"
        },
        {
          "id": 214895,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia </span></span></span></p>"
        },
        {
          "id": 214896,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male presents with complaints of excessive thirst (polydipsia) and frequent urination (polyuria), both during the day and at night. A 24-hour urine collection reveals a volume of 5 liters with an osmolality of 250 mOsm/L. Basal plasma ADH is 0.5pg/mL. MRI of the pituitary is shown. Which of the following is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-170840.png\" style=\"height:299px; width:300px\" /></span></span></p>",
      "unique_key": "Q7635996",
      "question_audio": null,
      "question_video": null,
      "map_id": 25441,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Primary polydipsia (DI)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s high urine output (&gt;40 mL/kg/24 hours), low urine osmolality (&lt;300 mOsm/L), low ADH levels (&lt; 1 pg/mL) and intact posterior pituitary bright spot are all consistent with primary polydipsia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Central DI:</span></strong><span style=\"font-size:12.0pt\"> MRI would have revealed an absent posterior pituitary bright spot. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Nephrogenic DI:</span></strong><span style=\"font-size:12.0pt\"> This is caused by resistance to ADH in the kidneys, and would typically present with ADH level of &gt; 1pg/mL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion):</span></strong><span style=\"font-size:12.0pt\"> This would not cause polyuria and polydipsia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Primary polydipsia is characterized by high urine output, low urine osmolality, low ADH levels, and an intact posterior pituitary bright spot on MRI.</span></span></span></p>",
      "correct_choice_id": 214895,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53816,
      "choices": [
        {
          "id": 214737,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lactotrophs </span></span></span></p>"
        },
        {
          "id": 214738,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gonadotrophs </span></span></span></p>"
        },
        {
          "id": 214739,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyrotrophs </span></span></span></p>"
        },
        {
          "id": 214740,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following pituitary cell type would appear earliest in the fetus?</span></span></span></p>",
      "unique_key": "Q5782914",
      "question_audio": null,
      "question_video": null,
      "map_id": 25411,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Corticotrophs</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs, the cells responsible for producing adrenocorticotropic hormone (ACTH), are the earliest to appear in the fetal pituitary gland, at around 6 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lactotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce prolactin and appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Gonadotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce FSH and LH and also appear around 12 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Thyrotrophs:</span></strong><span style=\"font-size:12.0pt\"> These cells produce TSH and also appear around 12 weeks of gestation. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/13/screenshot-2024-08-13-154029.png\" style=\"height:758px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticotrophs are the earliest pituitary cells to appear in the fetus, around 6 weeks of gestation.</span></span></span></p>",
      "correct_choice_id": 214740,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53829,
      "choices": [
        {
          "id": 214789,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
        },
        {
          "id": 214790,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism</span></span></span></p>"
        },
        {
          "id": 214791,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperprolactinemia</span></span></span></p>"
        },
        {
          "id": 214792,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most common feature of adult hypopituitarism?</span></span></p>",
      "unique_key": "Q8698550",
      "question_audio": null,
      "question_video": null,
      "map_id": 25420,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Hypogonadism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism even when other pituitary hormones are also deficient. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperprolactinemia:</span></strong><span style=\"font-size:12.0pt\"> Less common and usually associated with prolactinomas. Note that even hyperprolactinemia&rsquo;s are associated with hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GH deficiency:</span></strong><span style=\"font-size:12.0pt\"> Common, but not as frequent as hypogonadism in adults</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism is the most common presenting feature of adult hypopituitarism.</span></span></span></p>",
      "correct_choice_id": 214790,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53852,
      "choices": [
        {
          "id": 214881,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common cause is GH cell adenoma</span></span></span></p>"
        },
        {
          "id": 214882,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">25% co-secrete prolactin</span></span></span></p>"
        },
        {
          "id": 214883,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Malignancies are the commonest cause of death</span></span></span></p>"
        },
        {
          "id": 214884,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Survival is 10 years lesser in acromegalics</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with features suggestive of acromegaly. Which of the following is incorrect?</span></span></p>",
      "unique_key": "Q7725314",
      "question_audio": null,
      "question_video": null,
      "map_id": 25438,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Malignancies are the commonest cause of death</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While acromegaly can be associated with an increased risk of certain malignancies, the most common cause of death in patients with acromegaly is cardiovascular disease. This is due to the multiple effects of excess growth hormone on the cardiovascular system, including hypertension, left ventricular hypertrophy, and increased risk of arrhythmias and heart failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Most common cause is GH cell adenoma:</span></strong><span style=\"font-size:12.0pt\"> Common causes of acromegaly are densely or sparsely granulated GH cell adenoma (60%) &gt; Mixed GH cell and PRL cell adenoma (25%), Mammosomatotrope cell adenoma (10%)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 25% co-secrete prolactin:</span></strong><span style=\"font-size:12.0pt\"> A significant proportion of GH-secreting tumors also co-secrete prolactin, leading to symptoms such as galactorrhea and menstrual irregularities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Survival is 10 years lesser in acromegalics:</span></strong><span style=\"font-size:12.0pt\"> Untreated acromegaly can significantly reduce life expectancy, primarily due to cardiovascular complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most common cause of death in patients with acromegaly is cardiovascular disease, not malignancies.</span></span></span></p>",
      "correct_choice_id": 214883,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53847,
      "choices": [
        {
          "id": 214861,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN1 </span></span></span></p>"
        },
        {
          "id": 214862,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carney complex</span></span></span></p>"
        },
        {
          "id": 214863,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MEN4 </span></span></span></p>"
        },
        {
          "id": 214864,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister hall syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All of the following are familial pituitary tumour syndromes except? </span></span></span></p>",
      "unique_key": "Q2087152",
      "question_audio": null,
      "question_video": null,
      "map_id": 25433,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Pallister-Hall syndrome.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome (due to mutations in GLI3 gene) is a rare genetic disorder characterized by various developmental abnormalities, including hypothalamic hamartoma, imperforate anus, and polydactyly. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While hypothalamic hamartomas can cause endocrine dysfunction, Pallister-Hall syndrome is not primarily considered a familial pituitary tumor syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MEN1 (Multiple Endocrine Neoplasia type 1):</span></strong><span style=\"font-size:12.0pt\"> This syndrome is characterized by tumors of the parathyroid glands, pituitary gland, and pancreas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carney complex:</span></strong><span style=\"font-size:12.0pt\"> This syndrome is associated with various tumors, including pituitary adenomas, cardiac myxomas, and pigmented skin lesions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. MEN4 (Multiple Endocrine Neoplasia type 4):</span></strong><span style=\"font-size:12.0pt\"> This rare syndrome is similar to MEN1 but is caused by mutations in a different gene (CDKN1B).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pallister-Hall syndrome, characterized by hypothalamic hamartoma, imperforate anus, and polydactyly, is not primarily a familial pituitary tumor syndrome.</span></span></span></p>",
      "correct_choice_id": 214864,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53838,
      "choices": [
        {
          "id": 214825,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test </span></span></span></p>"
        },
        {
          "id": 214826,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">l-Arginine test </span></span></span></p>"
        },
        {
          "id": 214827,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test </span></span></span></p>"
        },
        {
          "id": 214828,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH stimulation test</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following tests are used for ACTH deficiency, except?</span></span></p>",
      "unique_key": "Q4778001",
      "question_audio": null,
      "question_video": null,
      "map_id": 25424,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) l-Arginine test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metyrapone test:</span></strong><span style=\"font-size:12.0pt\"> Tests the integrity of the hypothalamic-pituitary-adrenal (HPA) axis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. CRH test:</span></strong><span style=\"font-size:12.0pt\"> Directly stimulates the pituitary to release ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. ACTH stimulation test:</span></strong><span style=\"font-size:12.0pt\"> Assesses the adrenal glands&#39; ability to respond to ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Summary:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for ACTH deficiency: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH test (Standard &amp; low dose &ndash; test cortisol, level &gt; 21 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test (test cortisol, level &gt; 20 &mu;g/dL is normal)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRH test (test ACTH and cortisol, cortisol level &gt; 20 &mu;g/dL is normal). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metyrapone test (test 11 deoxy cortisol and ACTH) &ndash; outdated, not in use.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tests for GH deficiency: Insulin tolerance test, GHRH test, l-Arginine test, l-Dopa test, ghrelin test (macimoerlin test - ORAL) &amp; glucagon test. Facts on Adult GH deficiency -</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test is the 1<sup>st</sup> line test but C/I in diabetes, ischemic heart disease, cerebrovascular disease, epilepsy and elderly. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH &gt;3 &mu;g/L in response to hypoglycemia (&lt; 40mg/dL) is considered as the normal response (GH &lt; 3 &mu;g/L is suggestive of GH deficiency). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult GH deficiency is associated with changes in body composition (reduced lean body mass, increased fat mass with selective deposition of intraabdominal visceral fat, and increased waist-to-hip ratio), Hyperlipidemia, LV dysfunction, hypertension, and reduced bone mineral density.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult hypopituitarism is associated with a 3x increase in CV mortality</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The l-Arginine test is used to assess growth hormone (GH) reserve, not ACTH deficiency.</span></span></span></p>",
      "correct_choice_id": 214826,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53812,
      "choices": [
        {
          "id": 214721,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia (FHH) </span></span></span></p>"
        },
        {
          "id": 214722,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypocalcemia </span></span></span></p>"
        },
        {
          "id": 214723,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism (NSHPT) </span></span></span></p>"
        },
        {
          "id": 214724,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciuria</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing of a patient reveals a homozygous inactivating mutation in the calcium-sensing receptor (CaSR) gene. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7301258",
      "question_audio": null,
      "question_video": null,
      "map_id": 25407,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Neonatal severe hyperparathyroidism (NSHPT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">NSHPT</span></strong><span style=\"font-size:12.0pt\"> is a rare autosomal recessive disorder caused by homozygous or compound heterozygous inactivating mutations in the CaSR gene. This leads to severe hypercalcemia due to unsuppressed PTH secretion, often resulting in life-threatening complications in newborns.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Familial hypocalciuric hypercalcemia (FHH):</span></strong><span style=\"font-size:12.0pt\"> FHH is a milder autosomal dominant condition caused by heterozygous CaSR mutations, characterized by mild hypercalcemia and low urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Familial hypocalciuric hypocalcemia:</span></strong><span style=\"font-size:12.0pt\"> This is not a recognized condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Familial hypocalcemic hypercalciuria:</span></strong><span style=\"font-size:12.0pt\"> This is caused by activating CaSR mutations, leading to hypocalcemia and high urinary calcium excretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Calcium sensing receptor defects &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalciuric hypercalcemia - AD, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neonatal severe hyperparathyroidism- AR, inactivating</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Familial hypocalcemic hypercalciura- AD, activating</span></span></span></p>",
      "correct_choice_id": 214723,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53848,
      "choices": [
        {
          "id": 214865,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Verapamil</span></span></span></p>"
        },
        {
          "id": 214866,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Methyldopa</span></span></span></p>"
        },
        {
          "id": 214867,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Risperidone</span></span></span></p>"
        },
        {
          "id": 214868,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metoclopramide</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is most likely to cause a significant elevation in prolactin levels, often exceeding 200 &mu;g/L?</span></span></p>",
      "unique_key": "Q3057957",
      "question_audio": null,
      "question_video": null,
      "map_id": 25434,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Risperidone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PRL secreting pituitary adenomas (prolactinomas) are the most common cause of PRL levels &gt;200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other causes (drugs/ infiltrative disorders) that elevate PRL levels, usually have PRL in the range of 30&ndash;100 &mu;g/L. Risperidone, is an exception though since it can elevate PRL to levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Verapamil:</span></strong><span style=\"font-size:12.0pt\"> While verapamil is a calcium channel blocker and can mildly elevate prolactin levels, it typically doesn&#39;t cause levels exceeding 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Methyldopa:</span></strong><span style=\"font-size:12.0pt\"> Methyldopa is an antihypertensive that can also slightly increase prolactin, but not to the extent seen with risperidone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metoclopramide:</span></strong><span style=\"font-size:12.0pt\"> Metoclopramide is a dopamine antagonist used for nausea and gastroparesis, and it can elevate prolactin, but typically not to levels above 200 &mu;g/L.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Risperidone can significantly elevate prolactin levels, often exceeding 200 &mu;g/L.</span></span></span></p>",
      "correct_choice_id": 214867,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53856,
      "choices": [
        {
          "id": 214897,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Desmopressin (DDAVP) </span></span></span></p>"
        },
        {
          "id": 214898,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thiazides </span></span></span></p>"
        },
        {
          "id": 214899,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fluid restriction </span></span></span></p>"
        },
        {
          "id": 214900,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female with a history of psychiatric illness presents with polyuria and polydipsia. A 24-hour urine collection reveals a volume of 4 liters with an osmolality of 200 mOsm/L. Basal plasma ADH is 1.4 pg/mL. Which of the following is the best treatment?</span></span></p>",
      "unique_key": "Q8254692",
      "question_audio": null,
      "question_video": null,
      "map_id": 25442,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Thiazides</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s clinical presentation, with polyuria, polydipsia, dilute urine and increased ADH (&gt; 1 pg/mL) suggests a diagnosis of nephrogenic diabetes insipidus (NDI). In NDI, use of thiazides (&plusmn; Indomethacin) improves ADH sensitivity and hence, the preferred treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Desmopressin (DDAVP):</span></strong><span style=\"font-size:12.0pt\"> This is a synthetic analog of ADH and is used to treat central DI, where there is a deficiency of ADH. It would not be effective for NDI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fluid restriction:</span></strong><span style=\"font-size:12.0pt\"> Can treat SIADH but can worsen hypernatremia in NDI. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Glucocorticoids:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids are not indicated for the treatment of DI (can worsen DI by reducing ADH release)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thiazides are the preferred treatment for nephrogenic diabetes insipidus (NDI) as they improve ADH sensitivity and reduce polyuria.</span></span></p>",
      "correct_choice_id": 214898,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53825,
      "choices": [
        {
          "id": 214773,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyposmia</span></span></span></p>"
        },
        {
          "id": 214774,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism </span></span></span></p>"
        },
        {
          "id": 214775,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mirror movements</span></span></span></p>"
        },
        {
          "id": 214776,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following clinical features is uncommon in Kallmann syndrome?</span></span></p>",
      "unique_key": "Q9024110",
      "question_audio": null,
      "question_video": null,
      "map_id": 25418,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hyperacusis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kallmann syndrome is a genetic disorder (usually due to KAL mutations, X-linked) and is characterized by GnRH deficiency and hyposmia/anosmia due to olfactory bulb hypoplasia or agenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classically, the syndrome may also be associated with color blindness, optic atrophy, SNHL, cleft palate, renal abnormalities, cryptorchidism, and neurologic abnormalities such as mirror movements (mirror movements can also be seen in cerebral palsy, CVJ anomalies, ALS, Friedrich ataxia and phenylketonuria)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Hyposmia or anosmia:</span></strong><span style=\"font-size:12.0pt\"> This is a hallmark feature of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypogonadism:</span></strong><span style=\"font-size:12.0pt\"> This is the primary hormonal manifestation of Kallmann syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Mirror movements (bimanual synkinesis):</span></strong><span style=\"font-size:12.0pt\"> This is a relatively common associated feature in Kallmann syndrome, although not always present.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperacusis is uncommon in Kallmann syndrome, which primarily features hypogonadism and hyposmia/anosmia.</span></span></span></p>",
      "correct_choice_id": 214776,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53815,
      "choices": [
        {
          "id": 214733,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormone controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 25% of basal metabolic rate</span></span></span></p>"
        },
        {
          "id": 214734,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone exerts a permissive action on other hormones. </span></span></span></p>"
        },
        {
          "id": 214735,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Parathyroid hormone (PTH) is a key regulator of calcium and phosphorus homeostasis. </span></span></span></p>"
        },
        {
          "id": 214736,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vasopressin (ADH) is involved in the control of serum osmolality.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false?</span></span></p>",
      "unique_key": "Q8156990",
      "question_audio": null,
      "question_video": null,
      "map_id": 25410,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Aldosterone exerts a permissive action on other hormones.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Aldosterone</span></strong><span style=\"font-size:12.0pt\"> is a mineralocorticoid hormone primarily responsible for regulating sodium and potassium balance, which indirectly influences blood pressure and fluid volume. On the other hand, Cortisol exerts a permissive action, which is the ability of one hormone to enhance the responsiveness of a target organ to another hormone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thyroid hormone:</span></strong><span style=\"font-size:12.0pt\"> Correct. Thyroid hormone does play a significant role in regulating basal metabolic rate, affecting energy expenditure and heat production. It controls </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\">25% of BMR in most tissues. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Parathyroid hormone (PTH):</span></strong><span style=\"font-size:12.0pt\"> Correct. PTH is the primary regulator of calcium and phosphorus homeostasis, acting on bone, kidney, and intestine to maintain normal levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vasopressin (antidiuretic hormone):</span></strong><span style=\"font-size:12.0pt\"> Correct. Vasopressin regulates serum osmolality by controlling water reabsorption in the kidneys, thus maintaining fluid balance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aldosterone does not exert a permissive action on other hormones; this function is primarily attributed to cortisol.</span></span></span></p>",
      "correct_choice_id": 214734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 52104,
      "choices": [
        {
          "id": 207917,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It binds to an intracellular receptor and acts as a transcription factor. </span></span></span></p>"
        },
        {
          "id": 207918,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is stored in vesicles and released by exocytosis. </span></span></span></p>"
        },
        {
          "id": 207919,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It utilizes cyclic AMP (cAMP) as a second messenger. </span></span></span></p>"
        },
        {
          "id": 207920,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is derived from cholesterol.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with complaints of heat intolerance, weight loss, and palpitations. Physical examination reveals tachycardia, tremor, and exophthalmos. Which of the following statements is most likely true regarding the hormone responsible for her symptoms?</span></span></p>",
      "unique_key": "Q9998569",
      "question_audio": null,
      "question_video": null,
      "map_id": 25087,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) It binds to an intracellular receptor and acts as a transcription factor.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s symptoms and signs are characteristic of hyperthyroidism, most likely due to Graves&#39; disease. The primary hormone responsible for these manifestations is thyroxine (T4), which belongs to Group I hormones. Group I hormones are lipophilic and can readily cross the cell membrane to bind to intracellular receptors, ultimately affecting gene transcription.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. It is stored in vesicles and released by exocytosis:</span></strong><span style=\"font-size:12.0pt\"> This mechanism is characteristic of Group II hormones, such as peptide hormones and catecholamines.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It utilizes cyclic AMP (cAMP) as a second messenger:</span></strong><span style=\"font-size:12.0pt\"> While cAMP is a common second messenger, it is primarily used by Group II hormones that bind to cell surface receptors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. It is derived from cholesterol:</span></strong><span style=\"font-size:12.0pt\"> This is true for steroid hormones, which are also Group I hormones. However, thyroid hormones are derived from tyrosine and iodine, not cholesterol.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thyroid hormones, like thyroxine (T4), bind to intracellular receptors and act as transcription factors.</span></span></span></p>",
      "correct_choice_id": 207917,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53814,
      "choices": [
        {
          "id": 214729,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gs&alpha; </span></span></span></p>"
        },
        {
          "id": 214730,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSH receptor </span></span></span></p>"
        },
        {
          "id": 214731,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">LH receptor </span></span></span></p>"
        },
        {
          "id": 214732,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GHRH receptor</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 4-year-old girl presents with precocious puberty, caf&eacute;-au-lait spots, and bone pain. Radiographs reveal multiple bone lesions consistent with fibrous dysplasia. A mutation in which of the following genes is most likely responsible for her condition?</span></span></p>",
      "unique_key": "Q2890212",
      "question_audio": null,
      "question_video": null,
      "map_id": 25409,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Gs&alpha;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The girl&#39;s presentation is classic for McCune-Albright syndrome, a rare disorder caused by activating mutations in the Gs&alpha; gene. These mutations lead to constitutive activation of G protein-coupled receptors, resulting in excessive hormone production and the characteristic features of the syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. TSH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the TSH receptor gene are associated with thyroid disorders, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. LH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the LH receptor gene can cause familial male-limited precocious puberty or Leydig cell hypoplasia, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GHRH receptor:</span></strong><span style=\"font-size:12.0pt\"> Mutations in the GHRH receptor gene are associated with isolated growth hormone deficiency or gigantism, not McCune-Albright syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><u><span style=\"font-size:12.0pt\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diseases due to Gs&alpha; mutations &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acromegaly (Gs&alpha; mutations in the GHRH pathway)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">McCune Albright Syndrome (mosaic Gs&alpha; mutations)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Albright&rsquo;s hereditary osteodystrophy (AHO)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pseudopseudohypoparathyroidism (PPHP)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pseudohypoparathyroidism types 1b, 1c, and 2</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 214729,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53817,
      "choices": [
        {
          "id": 214741,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">DAX-1</span></span></span></p>"
        },
        {
          "id": 214742,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">T-pit</span></span></span></p>"
        },
        {
          "id": 214743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prop-1</span></span></span></p>"
        },
        {
          "id": 214744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WT-1</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following transcription factor is NOT required for the normal development of pituitary gland?</span></span></p>",
      "unique_key": "Q6995256",
      "question_audio": null,
      "question_video": null,
      "map_id": 25412,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) WT1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While WT1 is a transcription factor involved in the development of several organs, including the kidneys and gonads, it is not directly implicated in pituitary gland development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. DAX-1:</span></strong><span style=\"font-size:12.0pt\"> This is a nuclear receptor involved in sex determination, gonadotroph and adrenal gland development. Its absence can lead to pituitary hypoplasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. T-pit (TBX19):</span></strong><span style=\"font-size:12.0pt\"> This T-box transcription factor is crucial for the differentiation of corticotrophs (ACTH-producing cells) in the pituitary gland.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. PROP-1:</span></strong><span style=\"font-size:12.0pt\"> This paired-like homeodomain transcription factor is essential for the development of somatotrophs, lactotrophs, and thyrotrophs in the pituitary gland. Mutations in PROP-1 can cause combined pituitary hormone deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">WT1 is not required for the normal development of the pituitary gland.</span></span></span></p>",
      "correct_choice_id": 214744,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53819,
      "choices": [
        {
          "id": 214749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hyperglycemia </span></span></span></p>"
        },
        {
          "id": 214750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypotension </span></span></span></p>"
        },
        {
          "id": 214751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased intracranial pressure </span></span></span></p>"
        },
        {
          "id": 214752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Temporomandibular joint pain</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Growth hormone increases IGF -1 production from the liver. Which of the following is incorrect regarding the effect of IGF-1?</span></span></p>",
      "unique_key": "Q9329393",
      "question_audio": null,
      "question_video": null,
      "map_id": 25414,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Hyperglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 actually has insulin-like effects, promoting glucose uptake into cells and lowering blood glucose levels. Therefore, hyperglycemia (high blood sugar) would not be a direct effect of IGF-1 administration.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypotension:</span></strong><span style=\"font-size:12.0pt\"> IGF-1 can cause vasodilation, leading to hypotension. IGF-1 can result in fluid retention as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased intracranial pressure:</span></strong><span style=\"font-size:12.0pt\"> This is a rare but serious side effect of excessive IGF-1 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Temporomandibular joint pain:</span></strong><span style=\"font-size:12.0pt\"> This is a known side effect of IGF-1 therapy, possibly related to its effects on cartilage growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1 has insulin-like effects, promoting glucose uptake into cells and lowering blood glucose levels, thus not causing hyperglycemia.</span></span></span></p>",
      "correct_choice_id": 214749,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53821,
      "choices": [
        {
          "id": 214757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cortisol levels peak around midnight. </span></span></span></p>"
        },
        {
          "id": 214758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH acts on melanocortin-2 receptors. </span></span></span></p>"
        },
        {
          "id": 214759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inflammation decreases POMC expression. </span></span></span></p>"
        },
        {
          "id": 214760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">An exaggerated response to ACTH is a feature of Addison&#39;s disease.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements is regarding ATCH and Cortisol is correct?</span></span></span></p>",
      "unique_key": "Q7633832",
      "question_audio": null,
      "question_video": null,
      "map_id": 25416,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) ACTH acts on melanocortin-2 receptors.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH binds to melanocortin-2 receptors (MC2R) on adrenocortical cells, stimulating cortisol production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Cortisol levels peak around midnight:</span></strong><span style=\"font-size:12.0pt\"> Cortisol levels follow a circadian rhythm, peaking in the morning (</span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 6 AM) and reaching a nadir around midnight.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inflammation decreases POMC expression:</span></strong><span style=\"font-size:12.0pt\"> Inflammation/stress increases CRH and AVP release. CRH increased POMC (proopiomelanocortin) gene and ACTH production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. An exaggerated response to ACTH is a feature of Addison&#39;s disease:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Addison&#39;s disease is characterized by primary adrenal insufficiency, leading to a <em>decreased</em> cortisol response to ACTH stimulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH binds to melanocortin-2 receptors (MC2R) on adrenocortical cells, stimulating cortisol production.</span></span></span></p>",
      "correct_choice_id": 214758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53822,
      "choices": [
        {
          "id": 214761,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kisspeptin regulates GnRH release </span></span></span></p>"
        },
        {
          "id": 214762,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continuous GnRH suppresses FSH and LH</span></span></span></p>"
        },
        {
          "id": 214763,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSH shares a common &alpha; subunit with LH and FSH</span></span></span></p>"
        },
        {
          "id": 214764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids stimulate TSH release</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is incorrect?</span></span></p>",
      "unique_key": "Q5507070",
      "question_audio": null,
      "question_video": null,
      "map_id": 25417,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Glucocorticoids stimulate TSH release.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids, such as cortisol, inhibit TSH release. They act at the level of the hypothalamus and pituitary gland to suppress the hypothalamic-pituitary-thyroid (HPT) axis. This is part of the stress response, where energy resources are diverted away from growth and reproduction towards immediate survival needs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Kisspeptin plays a role in regulating GnRH release:</span></strong><span style=\"font-size:12.0pt\"> Brain Kisspeptin (from KISS1 gene) stimulates GnRH release, which in turn triggers the release of LH and FSH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Continuous GnRH administration suppresses FSH and LH release:</span></strong><span style=\"font-size:12.0pt\"> Continuous GnRH stimulation leads to downregulation of GnRH receptors on gonadotrophs, resulting in decreased FSH and LH secretion. This principle is utilized in GnRH agonist therapy for conditions like prostate cancer and endometriosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. TSH shares a common &alpha; subunit with LH and FSH:</span></strong><span style=\"font-size:12.0pt\"> The &alpha; subunit of TSH, LH, and FSH is identical, while their &beta; subunits confer specific biological activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucocorticoids inhibit TSH release, not stimulate it.</span></span></span></p>",
      "correct_choice_id": 214764,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53827,
      "choices": [
        {
          "id": 214781,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth failure</span></span></span></p>"
        },
        {
          "id": 214782,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypogonadism</span></span></span></p>"
        },
        {
          "id": 214783,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypothyroidism </span></span></span></p>"
        },
        {
          "id": 214784,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adrenal insufficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 12-year-old boy has a history of medulloblastoma treated with cranial irradiation. Which of the following is the most common?</span></span></p>",
      "unique_key": "Q5126295",
      "question_audio": null,
      "question_video": null,
      "map_id": 25419,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Growth failure</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">2/3<sup>rd</sup> of patients develop hormone insufficiency after </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 50 Gy (5000 rad) of radiation</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usually occurs over 5&ndash;15 years and usually reflects hypothalamic &gt; pituitary damage</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GH deficiency is the most common (Pattern GH</span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> FSH/LH </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\"> Thyroid </span><span style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&agrave;</span></span><span style=\"font-size:12.0pt\">ACTH)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypogonadism:</span></strong><span style=\"font-size:12.0pt\"> While hypogonadism (deficiency of sex hormones) can also occur due to radiation therapy, it usually manifests later than growth failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> Hypothyroidism (decreased thyroid hormone production) is another potential complication, but it is less common and often occurs later than growth failure and hypogonadism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adrenal insufficiency:</span></strong><span style=\"font-size:12.0pt\"> Adrenal insufficiency is the least common endocrine complication following cranial irradiation and typically manifests much later than the other hormonal deficiencies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Growth hormone deficiency is the most common endocrine disorder following cranial irradiation in children.</span></span></span></p>",
      "correct_choice_id": 214781,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53836,
      "choices": [
        {
          "id": 214817,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ipilimumab </span></span></span></p>"
        },
        {
          "id": 214818,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Pembrolizumab </span></span></span></p>"
        },
        {
          "id": 214819,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Nivolumab </span></span></span></p>"
        },
        {
          "id": 214820,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old male is being treated with immunotherapy. He presents with fatigue, headache, and visual disturbances. MRI reveals a pituitary mass. Which of the following medications is LEAST likely to be the cause of his symptoms?</span></span></p>",
      "unique_key": "Q8017697",
      "question_audio": null,
      "question_video": null,
      "map_id": 25422,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Rituximab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ipilimumab, pembrolizumab, and nivolumab are immune checkpoint inhibitors that can cause hypophysitis (inflammation of the pituitary gland). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ipilimumab:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Pituitary cells express CTLA-4 and up to 20% of patients receiving CTLA-4 inhibitors (e.g., ipilimumab) develop hypophysitis<strong> </strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pembrolizumab:</span></strong><span style=\"font-size:12.0pt\"> Hypophysitis is also reported with PD-1/PD-L1 inhibitors (e.g., pembrolizumab and nivolumab) and may show delayed presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nivolumab:</span></strong><span style=\"font-size:12.0pt\"> Hypophysitis is also reported with PD-1/PD-L1 inhibitors (e.g., pembrolizumab and nivolumab) and may show delayed presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab is least likely to cause hypophysitis among the listed immunotherapy medications.</span></span></span></p>",
      "correct_choice_id": 214820,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53839,
      "choices": [
        {
          "id": 214829,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">170 cms</span></span></span></p>"
        },
        {
          "id": 214830,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">176.5 cms</span></span></span></p>"
        },
        {
          "id": 214831,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">163.5 cms</span></span></span></p>"
        },
        {
          "id": 214832,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">168.5 cms</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old boy presented with short stature. His father&rsquo;s height is 175 cms, mother&rsquo;s height is 165 cms. His mid parental height is?</span></span></p>",
      "unique_key": "Q2877059",
      "question_audio": null,
      "question_video": null,
      "map_id": 25425,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) 176.5 cms</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Final height can be predicted using standardized scales (Bayley-Pinneau or Tanner-Whitehouse) or estimated by adding 6.5 cm (boys) or subtracting 6.5 cm (girls) from the midparental height.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">175+165/2= 170; 170 + 6.5= 176.5</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Final height can be estimated by adding 6.5 cm to the midparental height for boys.</span></span></span></p>",
      "correct_choice_id": 214830,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53840,
      "choices": [
        {
          "id": 214833,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low dose Growth Hormone</span></span></span></p>"
        },
        {
          "id": 214834,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High dose Growth Hormone</span></span></span></p>"
        },
        {
          "id": 214835,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-1</span></span></span></p>"
        },
        {
          "id": 214836,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High dose Corticosteroids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following can be used to treat Laron dwarfism?</span></span></span></p>",
      "unique_key": "Q1180940",
      "question_audio": null,
      "question_video": null,
      "map_id": 25426,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) IGF-1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laron dwarfism, also known as growth hormone insensitivity, is a rare genetic disorder caused by a deficiency or malfunction of growth hormone receptors. IGF-1 (Insulin-like Growth Factor 1), a hormone stimulated by growth hormone, is the primary mediator of growth. Therefore, recombinant IGF-1 therapy is the standard treatment for Laron dwarfism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low dose Growth Hormone:</span></strong><span style=\"font-size:12.0pt\"> Ineffective as the body cannot respond to GH due to receptor issues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. High dose Growth Hormone:</span></strong><span style=\"font-size:12.0pt\"> Ineffective and potentially harmful, as the body cannot utilize excess GH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. High dose Corticosteroids:</span></strong><span style=\"font-size:12.0pt\"> Long term corticosteroids can reduce GH release and impair growth in children.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Laron dwarfism is treated with IGF-1 (Insulin-like Growth Factor 1).</span></span></span></p>",
      "correct_choice_id": 214835,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53843,
      "choices": [
        {
          "id": 214845,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised ICP</span></span></span></p>"
        },
        {
          "id": 214846,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Permanent DI</span></span></span></p>"
        },
        {
          "id": 214847,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypopituitarism</span></span></span></p>"
        },
        {
          "id": 214848,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vision loss</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man with acromegaly underwent transsphenoidal surgery (TSS). All of the following are complications except?</span></span></p>",
      "unique_key": "Q8842012",
      "question_audio": null,
      "question_video": null,
      "map_id": 25429,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Raised ICP (Intracranial Pressure)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSS complications &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Operative mortality rate is </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 1%.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Transient DI and hypopituitarism in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 20%.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Permanent DI, CN damage, nasal septal perforation, visual disturbances in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 10%. Permanent side effects are rare after surgery for microadenomas.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CSF leaks (leading to intracranial hypotension) in </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 4% of patients.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rare complications: carotid artery injury, loss of vision, hypothalamic damage, and meningitis </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Permanent DI (Diabetes Insipidus):</span></strong><span style=\"font-size:12.0pt\"> Can occur due to damage to the posterior pituitary or pituitary stalk during surgery, leading to a deficiency of antidiuretic hormone (ADH).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hypopituitarism:</span></strong><span style=\"font-size:12.0pt\"> Can occur due to damage or removal of pituitary tissue, leading to deficiencies in various pituitary hormones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vision loss:</span></strong><span style=\"font-size:12.0pt\"> Can occur due to compression or damage to the optic chiasm or nerves during surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Raised intracranial pressure (ICP) is not a common complication of transsphenoidal surgery (TSS) for acromegaly.</span></span></span></p>",
      "correct_choice_id": 214845,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53850,
      "choices": [
        {
          "id": 214873,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prolactinoma</span></span></span></p>"
        },
        {
          "id": 214874,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-functioning pituitary adenoma</span></span></span></p>"
        },
        {
          "id": 214875,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ACTH secreting adenoma</span></span></span></p>"
        },
        {
          "id": 214876,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">TSHoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common type of pituitary adenoma?</span></span></p>",
      "unique_key": "Q2151742",
      "question_audio": null,
      "question_video": null,
      "map_id": 25436,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Nonfunctioning pituitary adenomas</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 43% of pituitary adenomas are nonfunctioning pituitary adenomas, which do not produce excess hormones. Prolactinomas are the most common type of <em>functional</em> pituitary adenoma (prevalence </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 40%) but nonfunctioning adenomas are more prevalent overall. Also </span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span style=\"font-size:12.0pt\"> 80% of macroadenomas are non-functioning.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Prolactinomas:&nbsp;</span></strong><span style=\"font-size:12.0pt\">These are the most common <em>functional</em> pituitary adenoma, but not the most common overall.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ACTH secreting</span></strong><span style=\"font-size:12.0pt\"> <strong>adenoma</strong>: These tumors are less common than prolactinomas and nonfunctioning adenomas.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. TSHoma:</span></strong><span style=\"font-size:12.0pt\"> These tumors are extremely rare and in-fact the least common. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Most common type of pituitary adenoma is non functioning pituitary adenoma</span></span></span></p>",
      "correct_choice_id": 214874,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53851,
      "choices": [
        {
          "id": 214877,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fasting insulin levels </span></span></span></p>"
        },
        {
          "id": 214878,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral glucose tolerance test </span></span></span></p>"
        },
        {
          "id": 214879,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 </span></span></span></p>"
        },
        {
          "id": 214880,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin tolerance test</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45-year-old male presents with gradual enlargement of his hands and feet, coarsening of facial features, and excessive sweating. He also reports frequent headaches and joint pain. Which of the following tests would be the initial screening test for this patient?</span></span></p>",
      "unique_key": "Q2929049",
      "question_audio": null,
      "question_video": null,
      "map_id": 25437,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Serum IGF-1</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 is the most reliable initial screening test for acromegaly. IGF-1 is produced in the liver in response to growth hormone (GH) and its levels are more stable than GH levels, which fluctuate throughout the day. Elevated IGF-1 levels are highly suggestive of GH excess.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Fasting insulin levels:</span></strong><span style=\"font-size:12.0pt\"> While insulin levels may be increased in acromegaly due to insulin resistance, it is neither a screening nor a confirmatory test. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Oral glucose tolerance test:</span></strong><span style=\"font-size:12.0pt\"> It is confirmatory test for GH excess, not a screening test. The diagnosis of acromegaly is confirmed by demonstrating the failure of GH suppression to &lt; 0.4 &mu;g/L (or &lt; 0.05 &mu;g/L with newer assays) within 1&ndash;2 h of an oral glucose load (75 g).&nbsp; About 20% of patients exhibit a paradoxical GH rise after glucose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Insulin tolerance test:</span></strong><span style=\"font-size:12.0pt\"> It is primarily used for confirming GH deficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Serum IGF-1 is the most reliable initial screening test for acromegaly due to its stable levels compared to fluctuating growth hormone levels.</span></span></span></p>",
      "correct_choice_id": 214879,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53854,
      "choices": [
        {
          "id": 214889,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Smoking</span></span></span></p>"
        },
        {
          "id": 214890,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low glucose</span></span></span></p>"
        },
        {
          "id": 214891,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low angiotensin II levels</span></span></p>"
        },
        {
          "id": 214892,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low glucocorticoids</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a trigger for ADH release? </span></span></p>",
      "unique_key": "Q3720389",
      "question_audio": null,
      "question_video": null,
      "map_id": 25440,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Low angiotensin II levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Angiotensin II is a potent stimulator of ADH release. Low levels of angiotensin II would therefore not trigger ADH release but rather suppress it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other triggers: Nausea, acute hypoglycemia, glucocorticoid deficiency, smoking, and, possibly, hyperangiotensinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">FACTS ON ADH:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ADH secretion is determined by &lsquo;osmoreceptors&rsquo; (anteromedial hypothalamus). </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Usual setpoint for ADH release = S.osm of ~275 mosmol/L and S.Na of 135 ~ meq/L. <em>Set point for thirst ~3% higher than ADH setpoint.</em></span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Set point decreases in the luteal phase (~1%) and pregnancy (~3%).<br />\r\n\tAlso, note that in pregnancy ADH clearance is increased (3x - 4x) due to placental N-terminal peptidase (which corresponds to physiologic polyuria, a.k.a gestational DI)</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">ADH actions: Antidiuresis (V2), Vasoconstriction &amp; vWF/FVIII release (V1A), ACTH release (V1B)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Site of ADH action in the kidney = Principal cells (Distal nephron &ndash; especially the medullary collecting duct)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maximum diuresis achievable (if no ADH) = ~50mOsm/L (UO ~0.2mL/kg/min, SG &lt; 1)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maximum antidiuresis (Max ADH 1-3 pg/mL) = = ~1200mOsm/L (UO = ~0.35mL/kg/min)</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Smoking:</span></strong><span style=\"font-size:12.0pt\"> Nicotine in cigarettes can stimulate ADH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Low blood glucose:</span></strong><span style=\"font-size:12.0pt\"> Hypoglycemia can trigger ADH release as part of a stress response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Low glucocorticoid levels:</span></strong><span style=\"font-size:12.0pt\"> Glucocorticoids (like cortisol) inhibit ADH release. Hence deficiency would trigger ADH release.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low levels of angiotensin II do not trigger ADH release but rather suppress it, as angiotensin II is a potent stimulator of ADH release.</span></span></span></p>",
      "correct_choice_id": 214891,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53857,
      "choices": [
        {
          "id": 214901,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum albumin </span></span></span></p>"
        },
        {
          "id": 214902,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypokalemia</span></span></span></p>"
        },
        {
          "id": 214903,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated BUN</span></span></span></p>"
        },
        {
          "id": 214904,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum uric acid</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of lung cancer presents with confusion, lethargy, and muscle cramps. Laboratory results revealed a serum sodium of 120 mEq/L and serum osmolality of 260 mOsm/kg. Urine osmolality is 450 mOsm/kg, and urine sodium is 40 mEq/L. BP is 120/80 mm Hg and her JVP is normal. Which of the following laboratory findings is consistent with a diagnosis?</span></span></p>",
      "unique_key": "Q5641386",
      "question_audio": null,
      "question_video": null,
      "map_id": 25443,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Low serum uric acid</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the patient presents with euvolemic hypo-osmolar hyponatremia, accompanied by increased urine osmolality (&gt; 100 mOsm/L) and elevated urine sodium (&gt; 25 mEq/L). These findings suggest a diagnosis of SIADH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Classic Features of SIADH: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clinical euvolemia.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased: S.Na, S. Osmolality.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased U.Osmolality and U.Na.</span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other features of SIADH: </span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased: BUN, Cr, Uric acid, Urate and Plasma renin activity.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normal: Cortisol, T4, albumin and Potassium.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Low serum albumin:</span></strong><span style=\"font-size:12.0pt\"> Serum albumin may be low in hypervolemic hyponatremia and may be slight high in hypovolemic hyponatremia. In SIADH it would be normal. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hypokalemia:</span></strong><span style=\"font-size:12.0pt\"> In SIADH, serum potassium would be normal. It may be reduced in hyper and hypovolemic hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Elevated BUN:</span></strong><span style=\"font-size:12.0pt\"> BUN is generally normal/low in SIADH. It may be elevated in hypervolemic and hypovolemic hyponatremia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Low serum uric acid is a characteristic finding in SIADH, along with euvolemic hyponatremia, low serum osmolality, and high urine osmolality and sodium.</span></span></span></p>",
      "correct_choice_id": 214904,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}